vs
Side-by-side financial comparison of DIVERSIFIED HEALTHCARE TRUST (DHC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
DIVERSIFIED HEALTHCARE TRUST is the larger business by last-quarter revenue ($379.6M vs $177.4M, roughly 2.1× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -5.6%, a 7.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -0.0%). Over the past eight quarters, DIVERSIFIED HEALTHCARE TRUST's revenue compounded faster (1.2% CAGR vs -0.2%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DHC vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $379.6M | $177.4M |
| Net Profit | $-21.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -12.6% | 3.9% |
| Net Margin | -5.6% | 1.6% |
| Revenue YoY | -0.0% | 5.0% |
| Net Profit YoY | 75.7% | — |
| EPS (diluted) | $-0.09 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $379.6M | $196.9M | ||
| Q3 25 | $388.7M | $179.5M | ||
| Q2 25 | $382.7M | $181.1M | ||
| Q1 25 | $386.9M | $168.9M | ||
| Q4 24 | $379.6M | $187.3M | ||
| Q3 24 | $373.6M | $168.6M | ||
| Q2 24 | $371.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-21.2M | — | ||
| Q3 25 | $-164.0M | $5.4M | ||
| Q2 25 | $-91.6M | $-4.8M | ||
| Q1 25 | $-9.0M | $4.8M | ||
| Q4 24 | $-87.4M | — | ||
| Q3 24 | $-98.7M | $-143.5M | ||
| Q2 24 | $-97.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -12.6% | 1.2% | ||
| Q3 25 | -43.4% | 3.5% | ||
| Q2 25 | -24.5% | 4.7% | ||
| Q1 25 | -2.7% | 1.2% | ||
| Q4 24 | -26.1% | 13.2% | ||
| Q3 24 | -26.5% | -82.8% | ||
| Q2 24 | -23.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -5.6% | — | ||
| Q3 25 | -42.2% | 3.0% | ||
| Q2 25 | -23.9% | -2.7% | ||
| Q1 25 | -2.3% | 2.8% | ||
| Q4 24 | -23.0% | — | ||
| Q3 24 | -26.4% | -85.1% | ||
| Q2 24 | -26.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.09 | $0.05 | ||
| Q3 25 | $-0.68 | $0.12 | ||
| Q2 25 | $-0.38 | $-0.11 | ||
| Q1 25 | $-0.04 | $0.10 | ||
| Q4 24 | $-0.37 | $0.38 | ||
| Q3 24 | $-0.41 | $-3.11 | ||
| Q2 24 | $-0.41 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.4M | $144.3M |
| Total DebtLower is stronger | $2.4B | — |
| Stockholders' EquityBook value | $1.7B | $653.9M |
| Total Assets | $4.4B | $1.2B |
| Debt / EquityLower = less leverage | 1.47× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $105.4M | $238.4M | ||
| Q3 25 | $201.4M | $246.3M | ||
| Q2 25 | $141.8M | $445.9M | ||
| Q1 25 | $302.6M | $493.6M | ||
| Q4 24 | $144.6M | $484.6M | ||
| Q3 24 | $256.5M | $453.8M | ||
| Q2 24 | $265.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $3.1B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.7B | $693.1M | ||
| Q3 25 | $1.7B | $727.2M | ||
| Q2 25 | $1.9B | $757.8M | ||
| Q1 25 | $1.9B | $798.5M | ||
| Q4 24 | $2.0B | $778.3M | ||
| Q3 24 | $2.0B | $749.6M | ||
| Q2 24 | $2.1B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.4B | $1.3B | ||
| Q3 25 | $4.7B | $1.3B | ||
| Q2 25 | $4.8B | $1.5B | ||
| Q1 25 | $5.0B | $1.6B | ||
| Q4 24 | $5.1B | $1.6B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 1.56× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.6M | — |
| Free Cash FlowOCF − Capex | $-166.4M | — |
| FCF MarginFCF / Revenue | -43.8% | — |
| Capex IntensityCapex / Revenue | 38.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-280.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-19.6M | $43.7M | ||
| Q3 25 | $-49.3M | $60.8M | ||
| Q2 25 | $53.0M | $12.0M | ||
| Q1 25 | $-3.2M | $35.5M | ||
| Q4 24 | $112.2M | $33.1M | ||
| Q3 24 | $21.1M | $53.9M | ||
| Q2 24 | $44.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-166.4M | $43.5M | ||
| Q3 25 | $-89.8M | $57.0M | ||
| Q2 25 | $18.8M | $9.3M | ||
| Q1 25 | $-42.9M | $26.9M | ||
| Q4 24 | $-89.5M | $31.0M | ||
| Q3 24 | $-26.1M | $49.8M | ||
| Q2 24 | $3.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -43.8% | 22.1% | ||
| Q3 25 | -23.1% | 31.7% | ||
| Q2 25 | 4.9% | 5.1% | ||
| Q1 25 | -11.1% | 15.9% | ||
| Q4 24 | -23.6% | 16.6% | ||
| Q3 24 | -7.0% | 29.6% | ||
| Q2 24 | 0.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 38.7% | 0.1% | ||
| Q3 25 | 10.4% | 2.2% | ||
| Q2 25 | 8.9% | 1.5% | ||
| Q1 25 | 10.2% | 5.1% | ||
| Q4 24 | 53.1% | 1.1% | ||
| Q3 24 | 12.6% | 2.4% | ||
| Q2 24 | 11.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DHC
| Senior Housing Operating Portfolio Segment | $323.4M | 85% |
| Rental Income | $56.2M | 15% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
